ARQT Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Arcutis Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.36 |
| 52 Week High | US$13.17 |
| 52 Week Low | US$1.76 |
| Beta | 1.18 |
| 1 Month Change | 4.50% |
| 3 Month Change | -23.30% |
| 1 Year Change | -2.34% |
| 3 Year Change | -69.95% |
| 5 Year Change | n/a |
| Change since IPO | -61.65% |
Recent News & Updates
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24
Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Recent updates
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis
Sep 26Arcutis Biotherapeutics: A Name To Accumulate
Sep 18Arcutis acquires privately-held biotech Ducentis BioTherapeutics
Sep 07Shareholder Returns
| ARQT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.7% | -0.4% | -0.6% |
| 1Y | -2.3% | 5.4% | 22.5% |
Return vs Industry: ARQT underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: ARQT underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| ARQT volatility | |
|---|---|
| ARQT Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ARQT's share price has been volatile over the past 3 months.
Volatility Over Time: ARQT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 296 | Frank Watanabe | www.arcutis.com |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis.
Arcutis Biotherapeutics, Inc. Fundamentals Summary
| ARQT fundamental statistics | |
|---|---|
| Market cap | US$967.79m |
| Earnings (TTM) | -US$217.42m |
| Revenue (TTM) | US$106.39m |
9.1x
P/S Ratio-4.5x
P/E RatioIs ARQT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARQT income statement (TTM) | |
|---|---|
| Revenue | US$106.39m |
| Cost of Revenue | US$7.46m |
| Gross Profit | US$98.93m |
| Other Expenses | US$316.36m |
| Earnings | -US$217.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | 92.99% |
| Net Profit Margin | -204.36% |
| Debt/Equity Ratio | 90.2% |
How did ARQT perform over the long term?
See historical performance and comparison